echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Oncogene: DCAF12 is a novel antagonist of anti-apoptotic protein IAPs

    Oncogene: DCAF12 is a novel antagonist of anti-apoptotic protein IAPs

    • Last Update: 2022-05-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit


    Associate Researcher Wang Chenji of Fudan University and Professor Li Liang of Zibo Central Hospital jointly published a paper titled " DCAF12 promotes apoptosis and inhibits NF-κB activation by acting as an endogenous antagonist of " Oncogene Magazine on April 22 , 2022 .
    The latest research results of IAPs .

     Apoptosis or programmed cell death is an evolutionarily conserved process that is required for normal development, homeostasis and integrity of multicellular organisms
    In normal cells, there is a good regulatory balance between pro-apoptotic proteins and anti-apoptotic proteins, and they work together to regulate apoptosis

    Tumor cells inhibit apoptosis by upregulating the activity of anti-apoptotic proteins, which ultimately leads to phenotypes such as malignant proliferation and drug resistance of tumors

    IAP (Inhibitor of apoptosis) is a highly conserved endogenous inhibitor of apoptosis protein, and its anti-apoptotic function depends on the interaction of the BIR domain with Caspase ( Caspase ) family proteins
    The dysfunction of IAP family proteins is usually closely related to pathological processes such as inflammation and tumorigenesis .
    When cells receive apoptotic signals, they activate a class of proteins called IAP antagonists, which bind to IAPs , release the inhibitory effect of IAPs , and promote Caspase activation .
    The reported IAP antagonists include SMAC , HtrA2 and XAF1 .

     DCAF12 is a substrate-recognition subunit of the Cullin 4 ( CUL4 ) E3 ubiquitin ligase complex
    The CRL4-DCAF12 complex can bind and mediate the ubiquitination degradation of multiple substrates such as MAGEA3 and YAP .
    A recent screening of Drosophila apoptosis-related genes found that the Drosophila homologous protein dcaf12 is a pro-apoptotic factor ( Dev Biol.
    ), but the specific molecular mechanism has not yet been elucidated.
    It is also unknown
    whether DCAF12 performs dcaf12 - like pro-apoptotic functions in cells .
    In this study, the team reported that human DCAF12 binds multiple IAP family proteins , including XIAP , cIAP1 , cIAP2 and BRUCE , by recognizing the BIR domain in IAPs .

    The pro-apoptotic function of IAP depends on its ability to bind to IAPs , but does not affect the protein stability of IAPs .
    When cells initiate apoptosis, DCAF12 translocates from the nucleus to the cytoplasm, blocking the interaction between XIAP and pro-apoptotic Caspases 3/7/9 , promoting the activation of Caspase 3/7/9 and the execution of apoptosis .
    In addition, this study also found that DCAF12 inhibited the activation of NF-κB signaling pathway in an IAPs binding -dependent manner .
    DCAF12 is downregulated in a variety of tumors, and its deletion enhances many phenotypes of malignant transformation such as tumor cell proliferation and invasion .
    These results suggest that the pro-apoptotic function of DCAF12 is independent of the function of the substrate-recognition subunit of CRL4 and is an evolutionarily conserved novel IAP antagonist .


    Molecular mechanism of DCAF12- dependent regulation of apoptosis by IAPs

    Jiao Dongyue and Chen Yingji, doctoral students of the School of Life Sciences of Fudan University, are the co-first authors of the paper, and Associate Researcher Wang Chenji and Professor Li Liang of Zibo Central Hospital are the co-corresponding authors of the paper

    Original link: https:// class="western" >

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.